Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Fate Therapeutics Inc Market Cap
Based on ratings from 6 stock analysts, the Fate Therapeutics Inc stock price is expected to increase by 78.61% in 12 months. This is calculated by using the average 12-month stock price forecast for Fate Therapeutics Inc. The lowest target is $3.5 and the highest is $12. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedFATE 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Fate Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on FATE. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of FATE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Neutral | $5 | Reiterates | Aug 22, 2024 |
| Gil Blum Needham | Hold | Reiterates | Aug 14, 2024 | |
| Edward Tenthoff Piper Sandler | Overweight | $6 | Upgrade | Jun 17, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Neutral | $5 | Maintains | May 16, 2024 |
| Etzer Darout BMO Capital | Market Perform | $6 | Maintains | May 10, 2024 |
| Edward Tenthoff Piper Sandler | Neutral | $4 | Maintains | May 10, 2024 |
| David Nierengarten Wedbush | Neutral | $5 | Maintains | May 10, 2024 |
| Bill Maughan Canaccord Genuity | Buy | $9 | Maintains | May 10, 2024 |
| David Nierengarten Wedbush | Neutral | $7 | Reiterates | May 6, 2024 |
| David Nierengarten Wedbush | Neutral | $7 | Reiterates | Apr 23, 2024 |
| Gil Blum Needham | Hold | Reiterates | Apr 11, 2024 | |
| Tazeen Ahmad B of A Securities | Underperform | $6 | Maintains | Mar 28, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Neutral | $7 | Reiterates | Mar 19, 2024 |
| Peter Lawson Barclays | Overweight | $10 | Maintains | Feb 27, 2024 |
| Etzer Darout BMO Capital | Market Perform | $7 | Maintains | Feb 27, 2024 |
| Matthew Biegler Oppenheimer | Perform | Reiterates | Feb 27, 2024 | |
| Michael Ulz Morgan Stanley | Equal-Weight | $7 | Maintains | Feb 27, 2024 |
| David Nierengarten Wedbush | Neutral | $7 | Maintains | Feb 27, 2024 |
| Mara Goldstein Mizuho | Buy | $8 | Maintains | Nov 20, 2023 |
| Michael Ulz Morgan Stanley | Equal-Weight | $3 | Maintains | Nov 13, 2023 |
When did it IPO
2013
Staff Count
181
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. J. Scott Wolchko
Market Cap
$408.8M
In 2023, FATE generated $63.5M in revenue, which was a decrease of -34.03% from the previous year. This can be seen as a signal that FATE's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
